At LUMC a large proportion of patients are those with inflammatory disorders, malignancies or organ dysfunction who are or will be treated with immunosuppressive drugs. These patients are at increased risk of reactivation TB if they harbor latent TB infection.
Thus, detection and preventive treatment of latent TB is important in this setting. However, the detection of latent TB infection in these patients can be challenging because the currently available diagnostic tests (tuberculin skin test and interferon gamma release assays) have limited sensitivity. We are starting research with the aim to improve the diagnosis of latent TB, which will include immunological tests but also innovative methods of chest radiography.